Table 3.
Outcome | Studies | Risk Difference [95% CI] (<1 Favors Robotic) |
Test of Heterogeneity | Quantification of Heterogeneity |
|
---|---|---|---|---|---|
Chi2 | p | ||||
Spleen preserving failure | 16–26 | −0.25 [−0.30, −0.19] | 27.22 | 0.002 | df = 10; I2 = 63% |
Open conversions | 16, 17, 19, 21, 22, 24–26 | −0.05 [−0.09, −0.01] | 9.41 | 0.22 | df = 7; I2 = 26% |
Overall complications | 16–19, 21, 25, 26 | −0.06 [−0.14, 0.02] | 2.15 | 0.91 | df = 6; I2 = 0% |
Complications—Clavien–Dindo grade 1–2 | 16, 18, 21 | −0.02 [−0.15, 0.11] | 1.00 | 0.61 | df = 2; I2 = 0% |
Complications—Clavien–Dindo grade ≥3 | 16, 18, 21, 22, 25, 26 | −0.04 [−0.11, 0.03] | 4.82 | 0.44 | df = 5; I2 = 0% |
POPF grade B/C | 16–18, 21, 22, 25, 26 | 0.00 [−0.06, 0.07] | 3.34 | 0.77 | df = 6; I2 = 0% |
Biochemical leaks | 16–18, 21, 26 | −0.04 [−0.14, 0.05] | 1.01 | 0.91 | df = 4; I2 = 0% |
Intra-/post-operative blood transfusions |
16, 17, 19, 21, 25, 26 | −0.03 [−0.09, 0.04] | 5.49 | 0.36 | df = 5; I2 = 9% |
Reoperation rate | 16, 17, 21, 22, 26 | 0.01 [−0.05, 0.07] | 3.86 | 0.42 | df = 4; I2 = 0% |
Hospital length of stay | 16–19, 21, 22, 25, 26 | −1.52 [−2.84, −0.20] | 25.16 | <0.001 | df = 7; I2 = 72% |